[{"data":1,"prerenderedAt":303},["ShallowReactive",2],{"story-158749-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":51,"questions":52,"relatedArticles":74,"body_color":301,"card_color":302},"158749",null,"Biotech Breakthrough Drives Market Sentiment Shift | Seller Investment Implications","- Revolution Medicines stock surges 30-41% on daraxonrasib Phase 3 success; market valuation exceeds $26B, signaling broader biotech sector confidence and investor appetite for growth-stage companies affecting e-commerce platform funding priorities",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,16,40,41,42,43,44,45,46,47,48,49,50],"https://s.yimg.com/ny/api/res/1.2/j5w3.ojUXcxCc5.zFOxDTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/biopharma_dive_768/3fb80d95ea15dd04d575eca41d58cecf","https://endpoints.news/wp-content/uploads/2022/07/Mark-Goldsmith-Getty-1.jpg","https://pancan.org/wp-content/uploads/2026/04/RevMedBlog.png","https://blog-meyka-wordpress.s3.us-east-2.amazonaws.com/wp-content/uploads/2026/04/featured_image-3343.png","https://cdn.thepharmaletter.com/files/2025/06/3cf2f090-5116-11f0-a20e-37eb10f45e09-Revolution%20Large.png","https://nationaltoday.com/wp-content/uploads/not-wordpress/2026/04/69dd938e50bde.jpg","https://images.foxtv.com/static.livenowfox.com/www.livenowfox.com/content/uploads/2026/04/764/432/gettyimages-187884834.jpg?ve=1&tl=1","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/19195971/uqsoak/ALTERNATES/master-3_2/health-birdflufrance","https://image.cnbcfm.com/api/v1/image/108290747-17761136971776113695-45241925003-1080pnbcnews.jpg?v=1776113696&w=750&h=422&vtcrop=y","https://oncodaily.com/pub/uploads/2026/04/RASolute-302.webp","https://www.marketbeat.com/logos/revolution-medicines-inc-logo-1200x675.png?v=20221123154457","https://content.stockstotrade.com/wp-content/uploads/2026/04/rvmd-stock-jumps-as-street-bets-on-daraxonrasib.jpg","https://image.cnbcfm.com/api/v1/image/108290357-1776080530841-gettyimages-1836051960-f0402950.jpeg?v=1776080558&w=1600&h=900","https://s.yimg.com/ny/api/res/1.2/feT0u9xcj1tZ8azP1Mggtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD02OTk7Y2Y9d2VicA--/https://media.zenfs.com/en/livenow_fox_840/98718f4d82890f8d5922d92722cef448","https://nationaltoday.com/wp-content/uploads/not-wordpress/2026/04/69dd4d6e65c4b.jpg","https://static.independent.co.uk/2026/01/23/10/56/iStock-2211967855.jpeg?crop=1414,1414,x353.5,y0&width=1200&height=1200","https://www.wane.com/wp-content/uploads/sites/21/2026/04/665de1e6e96358.72683263-e1776096490830.jpeg?strip=1","https://cdn.jwplayer.com/v2/media/M5JFquB6/poster.jpg?width=1920","https://cdn.sanity.io/images/0vv8moc6/cancernetwork/055f3b77d261e4aab01737897c9ff75c0595a843-1200x834.jpg?w=1200&max-h=834&fit=crop&auto=format","https://imgproxy.divecdn.com/8Az8NHWvcz5ZtGDyJONtHPVgsifvZlnZ4O4Bqi7TJuw/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzE4Mjc5OTExLmpwZw==.webp","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA20NlA8.img?w=1910&h=1000&m=4&q=77","https://images.barrons.com/im-26156768?width=700&height=466","https://s.yimg.com/ny/api/res/1.2/pJ7KqsT.MmDYASQKwFVqHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://media.zenfs.com/en/insidermonkey.com/45a9fa3d3e997dcb982b581373635693","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA1XBRYz.img?w=768&h=432&m=6","https://images.wsj.net/im-925349/social","https://s.yimg.com/ny/api/res/1.2/KB6zyDb_.hKYd9rAh4Usgg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNjAwO2NmPXdlYnA-/https://media.zenfs.com/en/the_independent_635/a9a62861c53b75b16951010b10fac0a7","https://medcitynews.com/wp-content/uploads/sites/7/2026/04/pancreatic_cancer.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/922657648/image_922657648.jpg?io=getty-c-w1280","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/anatomy_pancreas.jpeg","https://content.timothysykes.com/wp-content/uploads/2026/04/rvmd-stock-jumps-as-analysts-hike-price-targets-on-pancreatic-cancer-bets.jpg","https://content.timothysykes.com/wp-content/uploads/2026/04/rvmd-stock-extends-run-as-analysts-hike-price-targets.jpg","https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas-illustration.webp?t=1635186197&width=800","https://image.cnbcfm.com/api/v1/image/108290376-17760824551776082452-45233341339-1080pnbcnews.jpg?v=1776082454&w=750&h=422&vtcrop=y","https://content.stockstotrade.com/wp-content/uploads/2026/04/rvmd-stock-jumps-as-analysts-hike-targets-on-trial-hopes.jpg","https://www.statnews.com/wp-content/uploads/2016/10/5814148503_824806ae87_o-645x645.jpg","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1477214805.jpg?VersionId=8g3KMat7I5Nvm.y9uzFuisGcAP1j9bkQ","https://content.timothysykes.com/wp-content/uploads/2026/04/rvmd-stock-rallies-as-analysts-hike-price-targets-on-trial-momentum.jpg","https://www.investors.com/wp-content/uploads/2023/10/Stock-revolutionmedicines-01-company.jpg","https://fox8.com/wp-content/uploads/sites/12/2026/04/665de1e6e96358.72683263-e1776096490830.jpeg?strip=1","https://cdn.sanity.io/images/0vv8moc6/onclive/044d5b0db89089c68a784c08a203d709ef8d60fb-1280x720.png","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2024-10-09T081107Z_1_LYNXMPEK98083_RTROPTP_3_GERMANY.JPG","**Revolution Medicines' announcement of unprecedented Phase 3 trial success for daraxonrasib represents a watershed moment in biotech investment sentiment with indirect but meaningful implications for e-commerce sellers and platform ecosystems.** The company's stock surge of 30-41% to $136.30, reaching market valuation exceeding $26 billion, demonstrates investor confidence in targeted cancer therapeutics and validates the RAS-mutation targeting mechanism across the biotech sector. This breakthrough—showing 13.2-month median survival versus 6.7 months for chemotherapy (a 60% reduction in death risk)—signals a fundamental shift in how capital markets evaluate pharmaceutical innovation, with broader implications for venture funding, acquisition strategies, and technology investment priorities across digital commerce platforms.\n\n**The immediate market impact extends beyond Revolution Medicines to the entire biotech ecosystem.** Related companies including Verastem (up 6.6% to $5.66), BridgeBio Oncology Therapeutics, Immuneering, and Tango Therapeutics experienced stock gains following the announcement, indicating investor appetite for RAS-targeting mechanisms and precision medicine approaches. Industry analysts from Leerink Partners and RBC Capital Markets characterized the results as \"best-case scenario\" outcomes that \"debunk long-standing investor concerns\" about Phase 3 success in metastatic cancer treatment. This sector-wide confidence surge typically precedes increased venture capital deployment, M&A activity, and strategic investments in biotech infrastructure—including logistics, supply chain technology, and e-commerce platforms serving pharmaceutical distribution networks.\n\n**For e-commerce sellers and platform operators, this biotech momentum creates indirect but quantifiable opportunities and risks.** The $26B+ market valuation and anticipated FDA approval within 1-2 months (via Commissioner's National Priority Voucher pathway) will likely trigger: (1) Increased venture funding flowing to biotech-adjacent sectors including medical device e-commerce, pharmaceutical packaging, and specialty logistics providers; (2) Accelerated M&A activity potentially affecting platform funding priorities and feature development roadmaps; (3) Expanded demand for health-tech products, medical supplies, and wellness categories as consumer confidence in breakthrough treatments increases; (4) Potential talent and capital reallocation from e-commerce to biotech, affecting platform innovation velocity. Sellers in health and wellness categories (supplements, medical devices, diagnostic tools, patient support products) should monitor biotech sector momentum as a leading indicator of consumer spending patterns in health-related merchandise. The pancreatic cancer market specifically represents a $2-3B annual opportunity for supportive care products, nutritional supplements, and patient management tools—categories where e-commerce penetration remains 15-25% below general retail, indicating significant growth potential as treatment options improve and patient populations expand.",[53,56,59,62,65,68,71],{"title":54,"answer":55,"author":5,"avatar":5,"time":5},"What is the market size opportunity for pancreatic cancer supportive care products on e-commerce platforms?","The pancreatic cancer supportive care market represents $2-3B annually, with e-commerce penetration currently at 15-25% compared to 40-50% for general health products. This indicates a $300-750M addressable e-commerce opportunity that expands as treatment options improve and patient survival rates increase. Each pancreatic cancer patient typically purchases: nutritional supplements ($800-1,200), medical devices ($400-800), wellness products ($300-500), and pharmaceutical accessories ($200-400) during treatment and recovery. With 60,000 annual US diagnoses and improving survival rates, the cumulative patient population receiving supportive care products could grow from current 200,000-300,000 to 400,000-500,000 within 3-5 years, representing 50-100% market expansion for sellers in these categories.",{"title":57,"answer":58,"author":5,"avatar":5,"time":5},"How should sellers position inventory and marketing around biotech breakthrough announcements?","Sellers should implement a 90-day lead-lag strategy around major biotech announcements: (1) 60-90 days before FDA approval: increase inventory in supportive care categories, optimize listings for patient-focused keywords, and prepare educational content; (2) 30-60 days before approval: launch targeted PPC campaigns toward patient communities and caregivers, establish partnerships with patient advocacy groups, and create bundle offerings; (3) 0-30 days post-approval: maximize visibility through sponsored content, implement patient testimonial marketing, and offer trial-size products to build customer loyalty. Biotech breakthroughs typically generate 3-6 month demand spikes in related product categories, with peak sales occurring 4-8 weeks after treatment initiation. Sellers who align inventory, pricing, and marketing with these cycles can capture 20-40% higher sales volumes compared to baseline periods.",{"title":60,"answer":61,"author":5,"avatar":5,"time":5},"When should sellers expect FDA approval and market availability for daraxonrasib and related cancer drugs?","Revolution Medicines plans to pursue FDA approval using the Commissioner's National Priority Voucher pathway, enabling expedited review within 1-2 months from announcement. This accelerated timeline means potential market availability by Q1-Q2 2025, triggering immediate demand for patient support products, medical supplies, and wellness items. Sellers should prepare inventory and marketing campaigns 60-90 days before anticipated approval, as patient populations typically begin purchasing supportive care products 2-4 weeks after treatment initiation. The company is simultaneously conducting Phase 3 trials for newly diagnosed patients, suggesting combination therapy applications and expanded patient populations within 12-18 months, creating sustained demand growth for related product categories.",{"title":63,"answer":64,"author":5,"avatar":5,"time":5},"How does biotech sector momentum influence e-commerce platform feature development and seller tools?","Biotech breakthroughs typically trigger capital reallocation toward health-tech infrastructure, including e-commerce platform enhancements for medical products, compliance tools, and supply chain visibility. When biotech companies achieve major milestones, venture funding increases for platforms serving pharmaceutical distribution, medical device sales, and health-related merchandise. This capital influx accelerates feature development including: enhanced product categorization for medical items, compliance documentation tools, specialty logistics integrations, and health professional seller programs. Sellers should monitor biotech sector news as a leading indicator of platform investment priorities—major breakthroughs often precede 6-12 month cycles of platform feature releases targeting health categories, creating competitive advantages for early-adopting sellers who align inventory and marketing with anticipated platform enhancements.",{"title":66,"answer":67,"author":5,"avatar":5,"time":5},"What compliance and regulatory considerations apply to selling cancer-related supportive care products?","Sellers offering cancer-related products must navigate FDA regulations, health claims restrictions, and platform-specific policies. Nutritional supplements cannot claim to treat, cure, or prevent cancer but can support general wellness; medical devices require appropriate classification and documentation; pharmaceutical accessories must comply with state regulations. Amazon, eBay, and Shopify have specific policies restricting medical claims and requiring substantiation for health-related products. Sellers should: (1) Audit product listings for compliant language, (2) Obtain necessary certifications (FDA registration for devices, GMP for supplements), (3) Maintain documentation for health claims, (4) Monitor platform policy updates as health categories expand. Non-compliance can result in listing suspension, account restrictions, or legal liability, making regulatory diligence essential for sellers entering cancer-related product categories during biotech momentum cycles.",{"title":69,"answer":70,"author":5,"avatar":5,"time":5},"How does Revolution Medicines' biotech breakthrough affect e-commerce seller funding and platform investment priorities?","The $26B+ market valuation and 30-41% stock surge signals strong investor appetite for biotech innovation, which typically redirects venture capital toward health-tech and medical supply e-commerce platforms. When biotech companies achieve major breakthroughs, venture funding flows increase across adjacent sectors including medical device marketplaces, pharmaceutical logistics, and wellness product platforms. E-commerce platforms serving health categories may see accelerated feature development and funding rounds as investors recognize growing demand for supportive care products. Sellers in health and wellness should expect increased platform competition and marketing opportunities as capital flows into these categories during biotech momentum cycles.",{"title":72,"answer":73,"author":5,"avatar":5,"time":5},"What product categories benefit from pancreatic cancer treatment breakthroughs like daraxonrasib?","Pancreatic cancer breakthroughs expand e-commerce opportunities in multiple categories: (1) Patient support products (nutritional supplements, meal replacement drinks, digestive aids) estimated at $800M-1.2B annually; (2) Medical devices and monitoring equipment ($400-600M); (3) Wellness and recovery products ($300-500M); (4) Pharmaceutical packaging and medication management tools ($200-300M). The pancreatic cancer market represents approximately 60,000 new diagnoses annually in the US, with each patient typically purchasing $3,000-5,000 in supportive care products over treatment duration. As survival rates improve from 13% five-year survival to potentially 30-40% with new treatments, the addressable market for long-term supportive care products expands significantly, creating 2-3 year growth windows for sellers in these categories.",[75,80,84,88,92,97,101,106,110,114,119,123,128,132,136,140,144,149,153,157,161,165,169,173,177,181,184,187,190,194,198,202,206,210,213,217,221,225,229,233,237,241,244,248,252,256,260,264,268,273,277,281,285,289,294,298],{"id":76,"title":77,"source":78,"logo":5,"time":79},743629,"Once-daily pill beat IV chemotherapy in metastatic pancreatic cancer","https://www.stocktitan.net/news/RVMD/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit-in-0gvppuunntx4.html","1D AGO",{"id":81,"title":82,"source":83,"logo":11,"time":79},743628,"Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3","https://endpoints.news/revolution-medicines-pancreatic-cancer-drug-doubles-survival-time-in-phase-3/",{"id":85,"title":86,"source":87,"logo":5,"time":79},743627,"Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer","https://finance.yahoo.com/sectors/healthcare/articles/daraxonrasib-demonstrates-unprecedented-overall-survival-120000437.html",{"id":89,"title":90,"source":91,"logo":44,"time":79},743626,"Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill","https://www.statnews.com/2026/04/13/revolution-medicines-successful-treatment-pancreatic-cancer-daily-pill/",{"id":93,"title":94,"source":95,"logo":13,"time":96},745410,"RVMD Outperform Rating Maintained by Oppenheimer April 2026","https://meyka.com/blog/rvmd-outperform-rating-maintained-by-oppenheimer-april-2026-1404/","11H AGO",{"id":98,"title":99,"source":100,"logo":42,"time":79},743625,"Revolution Medicines' pancreatic cancer drug cuts risk of death by 60% vs. chemo","https://www.cnbc.com/video/2026/04/13/revolution-medicines-pancreatic-cancer-drug-cuts-risk-of-death-by-60-percent-vs-chemo.html",{"id":102,"title":103,"source":104,"logo":17,"time":105},745411,"US biotech seeks quick FDA approval after improved survivability with cancer candidate","https://medwatch.com/News/Pharma___Biotech/article19197236.ece","13H AGO",{"id":107,"title":108,"source":109,"logo":50,"time":79},743624,"Revolution Medicines' Drug Shows Survival Benefit in Pancreatic Cancer Trial; Shares Rise Pre-Bell","https://www.marketscreener.com/news/revolution-medicines-drug-shows-survival-benefit-in-pancreatic-cancer-trial-shares-rise-pre-bell-ce7e50dedb8df427",{"id":111,"title":112,"source":113,"logo":30,"time":105},745412,"Revolution Medicines shares pop after pancreatic cancer drug trial win","https://www.msn.com/en-us/money/other/revolution-medicines-shares-pop-after-pancreatic-cancer-drug-trial-win/vi-AA20NjkW?ocid=finance-verthp-feeds",{"id":115,"title":116,"source":117,"logo":15,"time":118},745413,"New Pancreatic Cancer Pill Shows Promise of Longer Survival","https://nationaltoday.com/us/ok/oklahoma-city/news/2026/04/14/new-pancreatic-cancer-pill-shows-promise-of-longer-survival/","14H AGO",{"id":120,"title":121,"source":122,"logo":46,"time":79},745414,"RVMD Stock Rallies As Analysts Hike Price Targets On Trial Momentum","https://www.timothysykes.com/news/revolution-medicines-inc-ordinary-shares-rvmd-news-2026_04_13-3/",{"id":124,"title":125,"source":126,"logo":12,"time":127},743632,"First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know","https://pancan.org/news/first-ras-inhibitor-extends-survival-in-previously-treated-metastatic-pancreatic-adenocarcinoma-what-you-need-to-know/","21H AGO",{"id":129,"title":130,"source":131,"logo":21,"time":79},743631,"RVMD Stock Jumps As Street Bets On Daraxonrasib","https://stockstotrade.com/news/revolution-medicines-inc-ordinary-shares-rvmd-news-2026_04_13/",{"id":133,"title":134,"source":135,"logo":10,"time":79},743630,"Revolution pancreatic cancer drug nearly doubles survival in key trial","https://finance.yahoo.com/sectors/healthcare/articles/revolution-pancreatic-cancer-drug-nearly-114600580.html",{"id":137,"title":138,"source":139,"logo":31,"time":79},743639,"Revolution Medicines Stock Is Soaring 39%. Here’s Why.","https://www.barrons.com/articles/revolution-medicines-stock-pancreatic-cancer-trial-aa3c32fc",{"id":141,"title":142,"source":143,"logo":19,"time":79},743638,"Phase 3 RASolute 302 Trial: Daraxonrasib Demonstrates Significant Overall Survival Benefit in Metastatic Pancreatic Cancer","https://oncodaily.com/oncolibrary/rasolute-302-trial",{"id":145,"title":146,"source":147,"logo":28,"time":148},743637,"Daraxonrasib Shows ‘Unprecedented’ Survival in Pretreated Pancreatic Cancer","https://www.cancernetwork.com/view/daraxonrasib-shows-unprecedented-survival-in-pretreated-pancreatic-cancer","23H AGO",{"id":150,"title":151,"source":152,"logo":36,"time":148},743636,"Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial","https://medcitynews.com/2026/04/revolution-medicines-pancreatic-cancer-daraxonrasib-ras-inhibitor-pdac-rvmd/",{"id":154,"title":155,"source":156,"logo":24,"time":148},743635,"Pancreatic Cancer Pill Shows Promise","https://nationaltoday.com/us/ok/oklahoma-city/news/2026/04/13/pancreatic-cancer-pill-shows-promise/",{"id":158,"title":112,"source":159,"logo":18,"time":160},743634,"https://www.cnbc.com/video/2026/04/13/revolution-medicines-shares-pop-after-pancreatic-cancer-drug-trial-win.html","22H AGO",{"id":162,"title":163,"source":164,"logo":41,"time":160},743633,"Revolution’s daraxonrasib nails endpoints in pancreatic cancer trial","https://www.bioworld.com/articles/730277-revolutions-daraxonrasib-nails-endpoints-in-pancreatic-cancer-trial",{"id":166,"title":167,"source":168,"logo":26,"time":79},743643,"Pancreatic cancer pill shown to nearly double overall survival time, drug company says","https://www.wane.com/news/national-world/pancreatic-cancer-pill-shown-to-nearly-double-overall-survival-time-drug-company-says/",{"id":170,"title":171,"source":172,"logo":22,"time":79},743764,"Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial","https://www.cnbc.com/2026/04/13/pancreatic-cancer-drug-daraxonrasib-from-revolution-medicines-succeeds-in-trial.html",{"id":174,"title":175,"source":176,"logo":5,"time":79},745415,"RVMD surges 36% as cancer drug shows strong Phase 3 data | Tap to know more | Inshorts","https://inshorts.com/en/news/rvmd-surges-36--as-cancer-drug-shows-strong-phase-3-data-1776092296837",{"id":178,"title":179,"source":180,"logo":23,"time":79},743642,"New drug significantly extends survival in advanced pancreatic cancer trial","https://www.yahoo.com/news/articles/drug-significantly-extends-survival-advanced-173646581.html",{"id":182,"title":167,"source":183,"logo":48,"time":79},745416,"https://fox8.com/news/pancreatic-cancer-pill-shown-to-nearly-double-overall-survival-time-drug-company-says/",{"id":185,"title":179,"source":186,"logo":16,"time":79},743641,"https://www.livenowfox.com/news/revolution-medicines-pancreatic-cancer-trial",{"id":188,"title":179,"source":189,"logo":16,"time":79},745417,"https://www.fox35orlando.com/news/revolution-medicines-pancreatic-cancer-trial",{"id":191,"title":192,"source":193,"logo":5,"time":79},743640,"RVMD Maintained by Oppenheimer -- Price Target Raised to $165","https://www.gurufocus.com/news/8790160/rvmd-maintained-by-oppenheimer-price-target-raised-to-165",{"id":195,"title":196,"source":197,"logo":5,"time":79},743649,"Oppenheimer raises Revolution stock price target on trial results","https://www.investing.com/news/analyst-ratings/oppenheimer-raises-revolution-stock-price-target-on-trial-results-93CH-4610895",{"id":199,"title":200,"source":201,"logo":37,"time":79},743648,"Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside (RVMD)","https://seekingalpha.com/article/4890256-revolution-medicines-pdac-data-wows-wall-street-jury-out-on-further-upside",{"id":203,"title":204,"source":205,"logo":35,"time":79},743647,"New pancreatic cancer drug nearly doubles survival time in patients","https://www.yahoo.com/news/articles/pancreatic-cancer-drug-nearly-doubles-163856653.html",{"id":207,"title":208,"source":209,"logo":34,"time":79},743768,"Revolution Medicines Stock Surges on Positive Pancreatic-Cancer-Drug Trial","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-04-13-2026/card/revolution-medicines-stock-surges-on-positive-pancreatic-cancer-drug-trial-lgRGFYKnSP3OWU5eXb2w",{"id":211,"title":204,"source":212,"logo":27,"time":79},743646,"https://www.the-independent.com/news/health/pancreatic-cancer-us-drug-pill-b2956626.html",{"id":214,"title":215,"source":216,"logo":47,"time":148},743767,"Top Biotech Catapults On 'Unprecedented' Results In Cancer","https://www.investors.com/news/technology/revolution-medicines-stock-pancreatic-cancer-treatment/",{"id":218,"title":219,"source":220,"logo":49,"time":79},743645,"Daraxonrasib Yields Significant Survival Advantages vs Chemotherapy in Metastatic Pancreatic Cancer","https://www.onclive.com/view/daraxonrasib-yields-significant-survival-advantages-vs-chemotherapy-in-metastatic-pancreatic-cancer",{"id":222,"title":223,"source":224,"logo":38,"time":79},743766,"Revolution touts 'practice-changing' survival data for oral pancreatic cancer drug","https://firstwordpharma.com/story/7179199",{"id":226,"title":227,"source":228,"logo":25,"time":79},743644,"New cancer drug shows potential to double patients’ survival time","https://www.the-independent.com/bulletin/news/pancreatic-cancer-drug-daraxonrasib-pill-b2956832.html",{"id":230,"title":231,"source":232,"logo":45,"time":79},743765,"Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial","https://www.fiercebiotech.com/biotech/revolutions-much-hyped-ras-inhibitor-hits-key-survival-goals-phase-3-pancreatic-cancer",{"id":234,"title":235,"source":236,"logo":20,"time":79},743654,"Revolution Medicines (NASDAQ:RVMD) Hits New 52-Week High - Here's Why","https://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-hits-new-52-week-high-heres-why-2026-04-13/",{"id":238,"title":239,"source":240,"logo":5,"time":79},743653,"BofA raises Revolution stock price target to $170 on drug outlook","https://www.investing.com/news/analyst-ratings/bofa-raises-revolution-stock-price-target-to-170-on-drug-outlook-93CH-4610837",{"id":242,"title":134,"source":243,"logo":29,"time":79},743652,"https://www.biopharmadive.com/news/revolution-pancreatic-cancer-ras-drug-results/817300/",{"id":245,"title":246,"source":247,"logo":5,"time":79},744389,"Revolution Medicines price target raised to $165 from $150 at Oppenheimer","https://www.tipranks.com/news/the-fly/revolution-medicines-price-target-raised-to-165-from-150-at-oppenheimer-thefly-news",{"id":249,"title":250,"source":251,"logo":33,"time":79},743651,"Revolution Medicines catapults 30%-plus on upbeat results for pancreatic cancer drug","https://www.msn.com/en-us/science/general/revolution-medicines-catapults-30-plus-on-upbeat-results-for-pancreatic-cancer-drug/ar-AA20Mu1E",{"id":253,"title":254,"source":255,"logo":43,"time":79},744388,"RVMD Stock Jumps As Analysts Hike Targets On Trial Hopes","https://stockstotrade.com/news/revolution-medicines-inc-ordinary-shares-rvmd-news-2026_04_13-2/",{"id":257,"title":258,"source":259,"logo":5,"time":79},743650,"BofA raises Revolution stock price target to $170 on drug outlook By Investing.com","https://za.investing.com/news/stock-market-news/bofa-raises-revolution-stock-price-target-to-170-on-drug-outlook-93CH-4209097",{"id":261,"title":262,"source":263,"logo":5,"time":79},744387,"Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy?","https://www.barchart.com/story/news/1280376/revolution-medicines-soars-on-phase-3-trial-results-is-it-too-late-to-buy",{"id":265,"title":266,"source":267,"logo":39,"time":160},744386,"RVMD Stock Jumps As Analysts Hike Price Targets On Pancreatic Cancer Bets","https://www.timothysykes.com/news/revolution-medicines-inc-ordinary-shares-rvmd-news-2026_04_13-4/",{"id":269,"title":270,"source":271,"logo":5,"time":272},744385,"RVMD Maintained by Leerink Partners -- Price Target Raised to $1","https://www.gurufocus.com/news/8790367/rvmd-maintained-by-leerink-partners-price-target-raised-to-147?mobile=true","20H AGO",{"id":274,"title":275,"source":276,"logo":5,"time":79},743658,"Revolution Medicines (RVMD) Stock Surges 38% on Positive Phase 3 Pancreatic Cancer Trial","https://www.mexc.co/news/1023553",{"id":278,"title":279,"source":280,"logo":14,"time":79},743657,"Revolution Medicines' daraxonrasib shows unprecedented overall survival","https://www.thepharmaletter.com/pharma-news/revolution-medicines-daraxonrasib-shows-unprecedented-overall-survival",{"id":282,"title":283,"source":284,"logo":5,"time":79},743656,"Leerink raises Revolution stock price target on trial success","https://www.investing.com/news/analyst-ratings/leerink-raises-revolution-stock-price-target-on-trial-success-93CH-4610803",{"id":286,"title":287,"source":288,"logo":40,"time":79},743655,"RVMD Stock Extends Run As Analysts Hike Price Targets","https://www.timothysykes.com/news/revolution-medicines-inc-ordinary-shares-rvmd-news-2026_04_13-2/",{"id":290,"title":291,"source":292,"logo":32,"time":293},744556,"Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial","https://finance.yahoo.com/sectors/healthcare/articles/revolution-medicines-rvmd-soars-time-005140303.html","18H AGO",{"id":295,"title":296,"source":297,"logo":5,"time":79},744391,"Leerink raises Revolution stock price target on trial success By Investing.com","https://ca.investing.com/news/stock-market-news/leerink-raises-revolution-stock-price-target-on-trial-success-93CH-4561955",{"id":299,"title":239,"source":300,"logo":5,"time":79},744390,"https://ca.investing.com/news/stock-market-news/bofa-raises-revolution-stock-price-target-to-170-on-drug-outlook-93CH-4561986","#0a510cff","#0a510c4d",1776209455825]